Get the Stockscreener App
4.7546
1.04%
-0.0554
Abeona Therapeutics Inc stock is traded at $4.7546, with a volume of 138.47K.
It is down -1.04% in the last 24 hours and down -12.01% over the past month.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
See More
Previous Close:
$4.81
Open:
$4.79
24h Volume:
138.47K
Relative Volume:
0.14
Market Cap:
$243.83M
Revenue:
-
Net Income/Loss:
$-54.19M
P/E Ratio:
-1.8429
EPS:
-2.58
Net Cash Flow:
$-37.34M
1W Performance:
-14.08%
1M Performance:
-12.01%
6M Performance:
-27.44%
1Y Performance:
-23.84%
1-Day Range:
$4.74
$4.855
1-Week Range:
$4.74
$5.54
52-Week Range:
$3.9328
$7.5401
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Name
Abeona Therapeutics Inc
Sector
Industry
Phone
646-813-4701
Address
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
4.755 | 246.65M | 0 | -54.19M | -37.34M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.44 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
636.71 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
441.80 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.56 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
181.88 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Mar-05-25 | Initiated | Oppenheimer | Outperform |
| Jul-03-24 | Initiated | H.C. Wainwright | Buy |
| May-30-24 | Initiated | Stifel | Buy |
| Nov-11-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Feb-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-10-19 | Resumed | Cantor Fitzgerald | Neutral |
| Aug-15-19 | Downgrade | Maxim Group | Buy → Hold |
| Aug-12-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-26-19 | Downgrade | Mizuho | Buy → Neutral |
| Jun-27-19 | Initiated | Mizuho | Buy |
| Oct-12-18 | Initiated | Mizuho | Buy |
| Jun-05-18 | Initiated | Seaport Global Securities | Buy |
| Nov-08-17 | Initiated | SunTrust | Buy |
| Oct-16-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-11-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Oct-10-17 | Initiated | Citigroup | Buy |
| Oct-05-17 | Reiterated | Maxim Group | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-18-17 | Reiterated | Maxim Group | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Jan-06-17 | Initiated | Jefferies | Buy |
| Sep-29-16 | Reiterated | Maxim Group | Buy |
View All
Abeona Therapeutics Inc Stock (ABEO) Latest News
Abeona Therapeutics (ABEO) Grants Equity Awards to New Employees - GuruFocus
Abeona Therapeutics (NASDAQ: ABEO) grants 71,035 restricted shares to 11 new employees - Stock Titan
How Abeona Therapeutics Inc. stock reacts to job market dataQuarterly Investment Review & Weekly Breakout Stock Alerts - newser.com
Is Abeona Therapeutics Inc. (PCJ) stock supported by free cash flow2025 Stock Rankings & Safe Entry Trade Reports - newser.com
Visualizing Abeona Therapeutics Inc. stock with heatmapsJuly 2025 Earnings & Smart Money Movement Alerts - newser.com
Applying big data sentiment scoring on Abeona Therapeutics Inc.July 2025 Closing Moves & Scalable Portfolio Growth Ideas - newser.com
Sentiment analysis tools applied to Abeona Therapeutics Inc. - newser.com
Sector ETF performance correlation with Abeona Therapeutics Inc.Forecast Cut & Capital Efficient Trade Techniques - newser.com
Can Abeona Therapeutics Inc. (PCJ) stock survive global slowdown2025 Earnings Impact & Short-Term Trading Opportunity Alerts - newser.com
Is Abeona Therapeutics Inc. stock oversold or undervaluedMarket Activity Report & Real-Time Chart Breakout Alerts - newser.com
What downside risks could hit Abeona Therapeutics Inc. (PCJ) stockJuly 2025 Review & Real-Time Market Sentiment Alerts - newser.com
How dovish Fed policy supports Abeona Therapeutics Inc. (PCJ) stockPortfolio Growth Summary & Accurate Buy Signal Notifications - newser.com
CMS assigns permanent J-code for Abeona’s RDEB therapy ZEVASKYN By Investing.com - Investing.com Australia
Should I hold or sell Abeona Therapeutics Inc. stock in 20252025 Price Action Summary & Weekly Market Pulse Alerts - newser.com
Can Abeona Therapeutics Inc. stock sustain institutional interestTrade Analysis Report & Community Consensus Trade Signals - newser.com
Will Abeona Therapeutics Inc. stock benefit from green energy trendsWall Street Watch & Daily Profit Focused Screening - newser.com
Is Abeona Therapeutics Inc. stock positioned for long term growthQuarterly Earnings Report & Technical Confirmation Trade Alerts - newser.com
Is Abeona Therapeutics Inc. (PCJ) stock a top dividend aristocrat candidateQuarterly Earnings Report & Low Risk High Reward Trade Ideas - newser.com
Why retail investors favor Abeona Therapeutics Inc. stockQuarterly Earnings Report & Risk Controlled Daily Plans - newser.com
Published on: 2025-10-31 02:43:41 - newser.com
Published on: 2025-10-26 04:17:05 - newser.com
Why Abeona Therapeutics Inc. (PCJ) stock could outperform next yearWeekly Trade Analysis & High Accuracy Swing Entry Alerts - newser.com
Abeona Therapeutics Inc. (ABEO) stock price, news, quote and history - Yahoo! Finance UK
Abeona Therapeutics Inc. (PCJ.F) stock price, news, quote and history - Yahoo! Finance Singapore
Abeona Therapeutics Gets Permanent CMS J-Code for Zevaskyn Gene Therapy - MarketScreener
Abeona Therapeutics Inc. Announces Permanent J-Code for ZEVASKYN® (prademagene Zamikeracel) - MarketScreener
Abeona Therapeutics announces permanent J-code for Zevaskyn (prademagene zamikeracel) - MarketScreener
Abeona Therapeutics Announces Permanent J-Code For Zevaskyn(Prademagene Zamikeracel) - TradingView
CMS assigns permanent J-code for Abeona’s RDEB therapy ZEVASKYN - Investing.com
Abeona Therapeutics (ABEO) Gains CMS Approval for ZEVASKYN J-cod - GuruFocus
Abeona Therapeutics stock rises after receiving permanent J-code for ZEVASKYN - Investing.com Nigeria
Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel) - The Manila Times
Abeona Therapeutics Announces Permanent J-Code for ZEVASKYN Gene Therapy, Enhancing Access to Treatment for Recessive Dystrophic Epidermolysis Bullosa - Quiver Quantitative
Abeona (NASDAQ: ABEO) secures CMS HCPCS J3389 for ZEVASKYN, effective Jan 2026 - Stock Titan
Abeona Therapeutics’ Gene Therapy Gets FDA Nod For Treating Rare Genetic Skin Disease - MSN
Will Abeona Therapeutics Inc. (PCJ) stock benefit from Fed rate cutsVolume Spike & Precise Buy Zone Identification - newser.com
Abeona Therapeutics Inc Stock (ABEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):